COVID-Era Trial Flexibilities, Equity Focus, Could Be Used To Reshape Cancer Study Enrollment
US FDA is open to keeping COVID-necessitated trial changes that may have had unexpected benefits. The agency is also looking at building on pandemic’s focus on health disparities and inequities to push for more generalizable and inclusive clinical trial designs.
You may also be interested in...
Ken Frazier says advocates need to ensure governments continue investing in global biosecurity.
At The Atlantic’s Health Equity Summit, panel discussions highlighted efforts to improve diversity in clinical trials of diseases like lupus, which disproportionately affects women of color.
FDA’s Rick Pazdur notes that while the agency recently allowed Amgen to conduct a key dose comparison study for its landmark KRAS inhibitor post-market it will be less willing to do this in the future, particularly in settings that are less refractory.